Hepatitis B core-related antigen: Are we near a treatment endpoint?

Different serological and virological markers in chronic hepatitis B patients guide staging of viral infection, and initiation and response to therapy. Due to the persistence of intrahepatic covalently closed circular DNA (cccDNA) in the hepatocyte nucleus, hepatitis B is not curable. Even after und...

Descripción completa

Detalles Bibliográficos
Autor principal: Gupta, Tarana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346455/
https://www.ncbi.nlm.nih.gov/pubmed/36158266
http://dx.doi.org/10.3748/wjg.v28.i27.3532
_version_ 1784761654062350336
author Gupta, Tarana
author_facet Gupta, Tarana
author_sort Gupta, Tarana
collection PubMed
description Different serological and virological markers in chronic hepatitis B patients guide staging of viral infection, and initiation and response to therapy. Due to the persistence of intrahepatic covalently closed circular DNA (cccDNA) in the hepatocyte nucleus, hepatitis B is not curable. Even after undetectable hepatitis B virus DNA levels, the persistence of hepatitis B surface antigen and novel markers such as hepatitis B core-related antigen (HBcrAg) indicate the persistence of intrahepatic cccDNA. In this study, HBcrAg levels at baseline and after 24 and 48 wk of antiviral therapy predicted hepatitis B e antigen seroconversion. Due to the poor sensitivity of assays and detectable levels in HBsAg-negative patients, the long-term utility of HBcrAg needs future research.
format Online
Article
Text
id pubmed-9346455
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-93464552022-09-23 Hepatitis B core-related antigen: Are we near a treatment endpoint? Gupta, Tarana World J Gastroenterol Letter to the Editor Different serological and virological markers in chronic hepatitis B patients guide staging of viral infection, and initiation and response to therapy. Due to the persistence of intrahepatic covalently closed circular DNA (cccDNA) in the hepatocyte nucleus, hepatitis B is not curable. Even after undetectable hepatitis B virus DNA levels, the persistence of hepatitis B surface antigen and novel markers such as hepatitis B core-related antigen (HBcrAg) indicate the persistence of intrahepatic cccDNA. In this study, HBcrAg levels at baseline and after 24 and 48 wk of antiviral therapy predicted hepatitis B e antigen seroconversion. Due to the poor sensitivity of assays and detectable levels in HBsAg-negative patients, the long-term utility of HBcrAg needs future research. Baishideng Publishing Group Inc 2022-07-21 2022-07-21 /pmc/articles/PMC9346455/ /pubmed/36158266 http://dx.doi.org/10.3748/wjg.v28.i27.3532 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Letter to the Editor
Gupta, Tarana
Hepatitis B core-related antigen: Are we near a treatment endpoint?
title Hepatitis B core-related antigen: Are we near a treatment endpoint?
title_full Hepatitis B core-related antigen: Are we near a treatment endpoint?
title_fullStr Hepatitis B core-related antigen: Are we near a treatment endpoint?
title_full_unstemmed Hepatitis B core-related antigen: Are we near a treatment endpoint?
title_short Hepatitis B core-related antigen: Are we near a treatment endpoint?
title_sort hepatitis b core-related antigen: are we near a treatment endpoint?
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346455/
https://www.ncbi.nlm.nih.gov/pubmed/36158266
http://dx.doi.org/10.3748/wjg.v28.i27.3532
work_keys_str_mv AT guptatarana hepatitisbcorerelatedantigenarewenearatreatmentendpoint

Ejemplares similares